Lopinavir/ritonavir-based second line antiretroviral treatment in children at National Pediatric Hospital, Phnom Penh, Cambodia

被引：0
|
作者：
Sophan Sam
Vibol Ung
Chantheany Huot
Bunnthy Chan
Kdan Yuvatha
Christian Courpotin
Guillaume Adam
Sopheak Ngin
Eric Nerrienet
Y Meng Chhour
机构：
[1] National Pediatric Hospital,HIV/Hepatitis Laboratory
[2] French Red Cross,undefined
[3] Institute Pasteur,undefined
来源：
Retrovirology | / 6卷 / Suppl 1期
关键词：
Virological Failure; Plasma Viral Load; Resistance Analysis; Immunological Failure; Generation ANRS;
D O I：
10.1186/1742-4690-6-S1-O25
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 36 条
  • [31] Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection
    Amin, Janaki
    Boyd, Mark A.
    Kumarasamy, Nagalingeswaran
    Moore, Cecilia L.
    Losso, Marcello H.
    Nwizu, Chidi A.
    Mohapi, Lerato
    Kerr, Stephen J.
    Sohn, Annette H.
    Teppler, Hedy
    Renjifo, Boris
    Molina, Jean-Michel
    Emery, Sean
    Cooper, David A.
    PLOS ONE, 2015, 10 (02):
  • [32] Predictors of treatment failure, time to switch and reasons for switching to second line antiretroviral therapy in HIV infected children receiving first line anti-retroviral therapy at a Tertiary Care Hospital in Ethiopia
    Haile, Gelila Solomon
    Berha, Alemseged Beyene
    BMC PEDIATRICS, 2019, 19 (1)
  • [33] Predictors of treatment failure, time to switch and reasons for switching to second line antiretroviral therapy in HIV infected children receiving first line anti-retroviral therapy at a Tertiary Care Hospital in Ethiopia
    Gelila Solomon Haile
    Alemseged Beyene Berha
    BMC Pediatrics, 19
  • [34] Induction with Lopinavir-Based Treatment Followed by Switch to Nevirapine-Based Regimen versus Non-Nucleoside Reverse Transcriptase Inhibitors-Based Treatment for First Line Antiretroviral Therapy in HIV Infected Children Three Years and Older
    Alvarez-Uria, Gerardo
    Pakam, Raghavakalyan
    Naik, Praveen Kumar
    Midde, Manoranjan
    PLOS ONE, 2014, 9 (09):
  • [35] Raltegravir Non-Inferior to Nucleoside Based Regimens in SECOND-LINE Therapy with Lopinavir/Ritonavir over 96 Weeks: A Randomised Open Label Study for the Treatment Of HIV-1 Infection (vol 10, e0118228, 2015)
    Amin, Janaki
    Boyd, Mark A.
    Kumarasamy, Nagalingeswaran
    Moore, Cecilia L.
    Losso, Marcello H.
    Nwizu, Chidi A.
    Mohapi, Lerato
    Kerr, Stephen J.
    Sohn, Annette H.
    Teppler, Hedy
    Renjifo, Boris
    Molina, Jean-Michel
    Emery, Sean
    Cooper, David A.
    PLOS ONE, 2015, 10 (10):
  • [36] Body composition and metabolic outcomes after 96 weeks of treatment with ritonavir-boosted lopinavir plus either nucleoside or nucleotide reverse transcriptase inhibitors or raltegravir in patients with HIV with virological failure of a standard first-line antiretroviral therapy regimen: a substudy of the randomised, open-label, non-inferiority SECOND-LINE study
    Boyd, Mark A.
    Amin, Janaki
    Mallon, Patrick W. G.
    Kumarasamy, Nagalingeswaran
    Lombaard, Johan
    Wood, Robin
    Chetchotisakd, Ploenchan
    Phanuphak, Praphan
    Mohapi, Lerato
    Azwa, Iskandar
    Belloso, Waldo H.
    Molina, Jean-Michel
    Hoy, Jennifer
    Moore, Cecilia L.
    Emery, Sean
    Cooper, David A.
    LANCET HIV, 2017, 4 (01): : E13 - E20
1234